These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 23791829)

  • 1. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors.
    Petrillo M; Fagotti A; Ferrandina G; Fanfani F; Costantini B; Vizzielli G; Pedone Anchora L; Nero C; Margariti PA; Scambia G
    Gynecol Oncol; 2013 Oct; 131(1):36-41. PubMed ID: 23791829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis.
    Petrillo M; Pedone Anchora L; Tortorella L; Fanfani F; Gallotta V; Pacciani M; Scambia G; Fagotti A
    Gynecol Oncol; 2014 Aug; 134(2):257-61. PubMed ID: 24910451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.
    Fagotti A; Petrillo M; Costantini B; Fanfani F; Gallotta V; Chiantera V; Turco LC; Bottoni C; Scambia G
    Gynecol Oncol; 2014 Feb; 132(2):303-6. PubMed ID: 24378877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
    Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
    Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study.
    Ferrero A; Ditto A; Giorda G; Gadducci A; Greggi S; Daniele A; Fuso L; Panuccio E; Scaffa C; Raspagliesi F; Sismondi P; Biglia N
    Eur J Surg Oncol; 2014 Jul; 40(7):891-8. PubMed ID: 24378007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
    Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.
    Kim CY; Jeong SY; Chong GO; Son SH; Jung JH; Kim DH; Lee SW; Ahn BC; Lee J
    Gynecol Oncol; 2015 Mar; 136(3):498-504. PubMed ID: 25557270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.
    Minaguchi T; Satoh T; Matsumoto K; Sakurai M; Ochi H; Onuki M; Oki A; Yoshikawa H
    Int J Clin Oncol; 2016 Jun; 21(3):573-9. PubMed ID: 26475355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases.
    Classe JM; Jaffre I; Frenel JS; Bordes V; Dejode M; Dravet F; Ferron G; Marchal F; Rigaud DB; Loussouarn D; Campion L
    Eur J Surg Oncol; 2011 Nov; 37(11):971-7. PubMed ID: 21944959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
    Deraco M; Virzì S; Iusco DR; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Grassi A; Baratti D; Kusamura S
    BJOG; 2012 Jun; 119(7):800-9. PubMed ID: 22571746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status.
    Gallotta V; Bruno M; Conte C; Giudice MT; Davià F; Moro F; Zannoni GF; Fagotti A; De Bonis M; Capoluongo E; Scambia G; Ferrandina G
    Eur J Surg Oncol; 2020 Jul; 46(7):1327-1333. PubMed ID: 32085925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients.
    Bakrin N; Cotte E; Golfier F; Gilly FN; Freyer G; Helm W; Glehen O; Bereder JM
    Ann Surg Oncol; 2012 Dec; 19(13):4052-8. PubMed ID: 22825772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of residual tumor locations in advanced ovarian cancer patients after incomplete primary cytoreduction.
    Grabowskil JP; Mardas M; Markowska A; Markowska J
    Eur J Gynaecol Oncol; 2015; 36(3):274-7. PubMed ID: 26189252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retroperitoneal lymph node recurrence of epithelial ovarian cancer: Prognostic factors and treatment outcome.
    Levy T; Migdan Z; Aleohin N; Ben-Shem ; Peled O; Tal O; Elyashiv O
    Gynecol Oncol; 2020 May; 157(2):392-397. PubMed ID: 32151375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Martinez A; Pomel C; Mery E; Querleu D; Gladieff L; Ferron G
    Gynecol Oncol; 2011 May; 121(2):258-63. PubMed ID: 21295334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of outcomes of secondary debulking surgery for recurrent epithelial ovarian cancer with favorable prognostic factors.
    Nasu K; Kai K; Hirakawa T; Nishida M; Matsumoto H; Kawano Y; Narahara H
    J Obstet Gynaecol Res; 2014 Mar; 40(3):791-6. PubMed ID: 24245582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence.
    Jamieson A; Sykes P; Eva L; Bergzoll C; Simcock B
    Gynecol Oncol; 2017 Aug; 146(2):273-278. PubMed ID: 28549816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?
    Kajiyama H; Mizuno M; Shibata K; Umezu T; Suzuki S; Yamamoto E; Mitsui H; Sekiya R; Niimi K; Kawai M; Nagasaka T; Kikkawa F
    Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():305-10. PubMed ID: 25203309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.